HomeAI · summaries
Storia in 9 fonti
AZ, Ionis shares tumble on ATTR-CM trial flop, but analyst flags over-reaction
The surprising failure of AstraZeneca and Ionis in a key phase 3 tria | The surprising failure of AstraZeneca and Ionis in a key phase 3 trial of Wainua in patients with ATTR-CM has sent the companies' shares tumbling, while those of their competitors are soaring. The CARDIO-TTRansform study did not meet its primary endpoint, which centered on reducing cardiovascular deaths or recurrent cardiovascular events through 140 weeks.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
AstraZeneca, Ionis drug fails big heart disease study in major setback
Eplontersen’s failure in transthyretin-mediated amyloidosis cardiomyopathy caught Wall Street analysts by surprise and boosted the outlook of rival drugs from Alnylam and…
- ·
cnbc.com
AstraZeneca stock dives 9% after heart drug trial misses target
A late-stage clinical trial failed to miss its primary endpoint, U.K.'s laregst drugmaker said Thursday.
